Alzheimer's disease is characterized by the accumulation of amyloid-beta protein, the amyloid cascade hypothesis suggests its deposition is fundamental in causing Alzheimer's pathology and cognitive decline.
Current advancements in Alzheimer’s treatments, specifically antiamyloid-beta monoclonal antibody therapies, focus on early-stage intervention to target and clear amyloid plaques, unlike traditional methods.
Early detection is crucial for Alzheimer's management, as intervention at initial stages with therapies such as donanemab or lecanemab can potentially slow cognitive decline.
While antiamyloid-beta MAB therapy offers a promising approach in Alzheimer's treatment, monitoring for amyloid-related imaging abnormalities (ARIA) is essential for patient safety.
Collection
[
|
...
]